GEN Exclusives

More »

GEN News Highlights

More »
May 27, 2014

BioInvent Gives Immunotherapy Candidate Back to Alligator Bioscience

  • BioInvent International just sold back all its rights to preclinical cancer candidate ADC-1013 to Alligator Bioscience after having manufactured ADC-1013 successfully. The firm says it still plans to fulfill the remaining chemistry, manufacturing, and control activities necessary to supply the drug to its first-in-human study, which both companies expect to start by the end of 2014.

    ADC-1013, according to Alligator, is an antibody-based immunotherapy that can induce antitumor immune effects by activating CD40 receptors on antigen-presenting dendritic cells. BioInvent describes the candidate as a FIND®-optimized n-CoDeR® antibody, FIND being Alligator's in vitro based antibody optimization technology and n-CoDeR being BioInvent's antibody library containing 20 billion human antibody genes. 

    Alligator’s CEO Sibylle Lenz said in a statement that the firm is pleased to be regaining full control over ADC-1013. "Cancer immunotherapy is a very exciting area and we have a strong support from our main investors to move ahead with the clinical trial as scheduled," she added.

    With its work with ADC-1013 being wrapped up, BioInvent says it plans to focus on its fully owned drug development candidates BI-505 (currently in Phase II for multiple myeloma) and BI-1206, which has a first-in-human study in non-Hodgkin’s lymphoma coming up in late 2014/early 2015.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »